The effect of mitotane on viability, steroidogenesis and gene expression in NCI-H295R adrenocortical cells

Molecular Medicine Reports

Volumn 7, Issue 3, 2013, Pages 893-900

  Lehmann, Tomasz P ^a   Wrzesiński, Tomasz ^a   Jagodziński, Paweł P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Adrenal; Cancer; Gene expression; O,p' DDD

Indexed keywords

CASPASE 3; CASPASE 7; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOCHROME P450; MESSENGER RNA; MITOTANE; TRANSFORMING GROWTH FACTOR BETA1;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX CELL; ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C MYC; OUTCOME ASSESSMENT; STEROIDOGENESIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL SURVIVAL; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; CYCLIC AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEHYDROEPIANDROSTERONE SULFATE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROCORTISONE; MITOTANE; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; STEROID 17-ALPHA-HYDROXYLASE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84873162193     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1244     Document Type: Article

References (46)

1. Hahner S and Fassnacht M: Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6:386-394, 2005. (Pubitemid 40561415)
2. Huang H and Fojo T: Adjuvant mitotane for adrenocortical cancer. a recurring controversy. J Clin Endocrinol Metab 93:3730-3732, 2008.
3. Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR and Baudin E: Plasma concentrations of o, p'DDD, o, p'DDA and o, p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96:1844-1851, 2011.
4. Allolio B and Fassnacht M: Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91:2027-2037, 2006. (Pubitemid 43854976)
5. Libe R, Fratticci A and Bertherat J: Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14:13-28, 2007. (Pubitemid 47521719)
6. Kirschner LS: Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 91:14-21, 2006. (Pubitemid 43069108)
7. Zini L, Porpiglia F and Fassnacht M: Contemporary management of adrenocortical carcinoma. Eur Urol 60:1055-1065, 2011.
8. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ and Krans HM: Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947-951, 1994. (Pubitemid 24140681)
9. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP and Le Bouc Y: Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61:6762-6767, 2001. (Pubitemid 32896498)
10. Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reynies A and Bertherat J: Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 70:8276-8281, 2010.
11. Asp V, Ulleras E, Lindstrom V, Bergstrom U, Oskarsson A and Brandt I: Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3.methylsulfonyl. DDE in human cells. Toxicol Appl Pharmacol 242:281-289, 2010.
12. Lin CW, Chang YH and Pu HF: Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-sP-s-s295 cells. Toxicology 298:14-23, 2012.
13. Gilep AA, Sushko TA and Usanov SA: At the crossroads of steroid hormone biosynthesis: the role, substrate specificity and evolutionary development of CYP17. Biochim Biophys Acta 1814:200-209, 2011.
14. Chung BC, Picado-Leonard J, Haniu M, Bienkowski M, Hall PF, Shively JE and Miller WL: Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17, 20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci USA 84:407-411, 1987. (Pubitemid 17006204)
15. Miller WL: Minireview: regulation of steroidogenesis by electron transfer. Endocrinology 146:2544-2550, 2005. (Pubitemid 40695556)
16. Staels B, Hum DW and Miller WL: Regulation of steroidogenesis in NCI-H295 cells: a cellular model of the human fetal adrenal. Mol Endocrinol 7:423-433, 1993. (Pubitemid 23104530)
17. Ahlman H, Khorram-Manesh A, Jansson S, Wangberg B, Nilsson O, Jacobsson CE and Lindstedt S: Cytotoxic treatment of adrenocortical carcinoma. World J Surg 25:927-933, 2001. (Pubitemid 32666395)
18. Pushkarev VM, Tronko ND, Kostyuchenko NN and Mikosha AS: Effect of o, p'. DDD and Li+ on apoptotic DNA fragmentation in conventionally normal and tumour tissues of human adrenal cortex. Ukr Biokhim Zh 79:44-49, 2007. (Pubitemid 47326146)
19. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E, Berger F, Gicquel C, Chabre O and Feige JJ: Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90:1819-1829, 2005. (Pubitemid 40464057)
20. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S and Lichter P: Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28:145-152, 2000. (Pubitemid 30246992)
21. Kjellman M, Kallioniemi OP, Karhu R, Hoog A, Farnebo LO, Auer G, Larsson C and Backdahl M: Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res 56:4219-4223, 1996. (Pubitemid 26305019)
22. Stephan EA, Chung TH, Grant CS, Kim S, Von Hoff DD, Trent JM and Demeure MJ: Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther 7:425-431, 2008. (Pubitemid 351302536)
23. Moore CC, Hum DW and Miller WL: Identification of positive and negative placenta-specific basal elements and a cyclic adenosine 3', 5'.monophosphate response element in the human gene for P450scc. Mol Endocrinol 6:2045-2058, 1992. (Pubitemid 23021554)
24. Sewer MB, Nguyen VQ, Huang CJ, Tucker PW, Kagawa N and Waterman MR: Transcriptional activation of human CYP17 in H295R adrenocortical cells depends on complex formation among p54 (nrb)/NonO, protein. associated splicing factor and SF.1, a complex that also participates in repression of transcription. Endocrinology 143:1280-1290, 2002. (Pubitemid 34274358)
25. Asp V, Lindstrom V, Olsson JA, Bergstrom U and Brandt I: Cytotoxicity and decreased corticosterone production in adrenocortical Y.1 cells by 3.methylsulfonyl. DDE and structurally related molecules. Arch Toxicol 83:389-396, 2009.
26. Shi YQ, Li HW, Wang YP, Liu CJ and Yang KD: p, p'. DDE induces apoptosis and mRNA expression of apoptosis-associated genes in testes of pubertal rats. Environ Toxicol: Mar. 7, 2011 (Epub ahead of print).
27. Burow ME, Tang Y, Collins-Burow BM, Krajewski S, Reed JC, McLachlan JA and Beckman BS: Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF.7 cells. Carcinogenesis 20:2057-2061, 1999. (Pubitemid 29535305)
28. Boatright KM and Salvesen GS: Mechanisms of caspase activation. Curr Opin Cell Biol 15:725-731, 2003. (Pubitemid 37492933)
29. Lakhani SA, Masud A, Kuida K, Porter GA Jr, Booth CJ, Mehal WZ, Inayat I and Flavell RA: Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311:847-851, 2006. (Pubitemid 43228848)
30. Alenzi FQ, Lotfy M and Wyse R: Swords of cell death: caspase activation and regulation. Asian Pac J Cancer Prev 11:271-280, 2010.
31. Fuentes-Prior P and Salvesen GS: The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J 384:201-232, 2004. (Pubitemid 39656233)
32. Hogel H, Rantanen K, Jokilehto T, Grenman R and Jaakkola PM: Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells. PLoS One 6:e27112, 2011.
33. Wilhelm S, Wagner H and Hacker G: Activation of caspase-3-like enzymes in non. apoptotic T cells. Eur J Immunol 28:891-900, 1998. (Pubitemid 28116202)
34. Feige JJ, Cochet C and Chambaz EM: Type beta transforming growth factor is a potent modulator of differentiated adrenocortical cell functions. Biochem Biophys Res Commun 139:693-700, 1986. (Pubitemid 16002482)
35. Riopel L, Branchaud CL, Goodyer CG, Adkar V and Lefebvre Y: Growth-inhibitory effect of TGF-B on human fetal adrenal cells in primary monolayer culture. J Cell Physiol 140:233-238, 1989. (Pubitemid 19185986)
36. Ragazzon B, Cazabat L, Rizk-Rabin M, Assie G, Groussin L, Fierrard H, Perlemoine K, Martinez A and Bertherat J: Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells. Cancer Res 69:7278-7284, 2009.
37. Khaidakov M, Szwedo J, Mitra S and Mehta JL: Angiostatic effects of aspirin in hypoxia-reoxygenation are linked to modulation of TGFbeta1 signaling. J Cardiovasc Pharmacol Ther 16:105-110, 2011.
38. Nieminen AI, Partanen JI and Klefstrom J: c-Myc blazing a trail of death: coupling of the mitochondrial and death receptor apoptosis pathways by c-Myc. Cell Cycle 6:2464-2472, 2007. (Pubitemid 350058664)
39. Prendergast GC: Mechanisms of apoptosis by c. Myc. Oncogene 18:2967-2987, 1999.
40. Gartel AL and Tyner AL: The role of the cyclin. dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1:639-649, 2002.
41. Shin H, Lee YS and Lee YC: Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells. Oncol Rep 27:1111-1115, 2012.
42. Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y and Akahane K: Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ 7:721-728, 2000. (Pubitemid 30599253)
43. Tait SW and Green DR: Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11:621-632, 2011.
44. Chen CW, Hurd C, Vorojeikina DP, Arnold SF and Notides AC: Transcriptional activation of the human estrogen receptor by DDT isomers and metabolites in yeast and MCF.7 cells. Biochem Pharmacol 53:1161-1172, 1997. (Pubitemid 27224262)
45. Gell JS, Oh J, Rainey WE and Carr BR: Effect of estradiol on DHEAS production in the human adrenocortical cell line, H295R. J Soc Gynecol Investig 5:144-148, 1998. (Pubitemid 28248540)
46. Vanttinen T, Liu J, Kuulasmaa T, Kivinen P and Voutilainen R: Expression of activin/inhibin signaling components in the human adrenal gland and the effects of activins and inhibins on adrenocortical steroidogenesis and apoptosis. J Endocrinol 178:479-489, 2003. (Pubitemid 37220174)